Evidence map›Paper›PMID 32139381›Full record

Trial reportDiabetes care2020

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.

W Timothy Garvey, Andreas L Birkenfeld, Dror Dicker, Geltrude Mingrone, Sue D Pedersen, Altynai Satylganova, Dorthe Skovgaard, Danny Sugimoto, Camilla Jensen, Ofri Mosenzon

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02963922. Cited by 75 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 19 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02963922 phase3completed

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Ran2017Enrolled396Registered outcomes46Posted comparisons4ConditionsMetabolism and Nutrition Disorder, ObesityArmsLiraglutide 3.0 mg, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 19 syntheses or guidelines pooled it, 172 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 7 countries.

W Timothy GarveyDepartment of Nutrition Sciences, The University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, AL garveyt@uab.edu.ORCID 0000-0003-0822-0860
Andreas L BirkenfeldDepartment of Diabetology, Endocrinology, and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany.ORCID 0000-0003-1407-9023
Dror DickerInternal Medicine D, Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel.ORCID 0000-0001-8546-6245
Geltrude MingroneDivision of Diabetes and Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, London, U.K.ORCID 0000-0003-2021-528X
Sue D PedersenC-ENDO Diabetes and Endocrinology Clinic, Calgary, Alberta, Canada.
Altynai SatylganovaNovo Nordisk A/S, Søborg, Denmark.
Dorthe SkovgaardNovo Nordisk A/S, Søborg, Denmark.
Danny SugimotoCedar Crosse Research Center, Chicago, IL.
Camilla JensenNovo Nordisk A/S, Søborg, Denmark.
Ofri MosenzonDiabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Novo Nordisk (Denmark) · DKHebrew University of Jerusalem · ILKing's College London · GBLMC Diabetes & Endocrinology (Canada) · CATel Aviv University · ILUniversità Cattolica del Sacro Cuore · ITUniversity of Alabama at Birmingham · US

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Stuart J Frank · 2013 to 2026
$19.5M
NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

objectiveMost individuals with type 2 diabetes also have obesity, and treatment with some diabetes medications, including insulin, can cause further weight gain. No approved chronic weight management medications have been prospectively investigated in individuals with overweight or obesity and insulin-treated type 2 diabetes. The primary objective of this study was to assess the effect of liraglutide 3.0 mg versus placebo on weight loss in this population. RESEARCH DESIGN AND

methodsSatiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.

resultsIndividuals were randomized to liraglutide 3.0 mg (

conclusionsIn individuals with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg as an adjunct to IBT was superior to placebo regarding weight loss and improved glycemic control despite lower doses of basal insulin and without increases in hypoglycemic events.

Indexed as

AdiposityAdultAgedBehavior TherapyBlood GlucoseCombined Modality TherapyDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleGlycated HemoglobinHumansInsulinLiraglutideMaleMiddle AgedBlood GlucoseGlycated HemoglobinInsulinLiraglutide

Identifiers

PMID32139381
PMCPMC7171937
OpenAlexW3010125829

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.